GlassScriptPhysician profile
Shayna Gordon
NPI 1679849780
$4,492.03
in general payments reported to CMS, 2019-2025
36 companies · $934 in 2025
The $934 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $581 · 2021: $855 · 2022: $789 · 2023: $265 · 2024: $283 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,307 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,306.83 |
| Education | $175.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $836.78 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $641.38 | 2019-2025 | |
| Lilly USA, LLC | $340.79 | 2019-2023 | Olumiant, Taltz |
| Janssen Biotech, INC. | $329.21 | 2021-2025 | Tremfya |
| Pfizer INC. | $273.57 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $232.70 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $225.45 | 2019-2025 | Libtayo, Dupixent |
| Leo Pharma INC. | $201.09 | 2019-2025 | Anzupgo |
| Galderma Laboratories, L.P. | $168.24 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Ucb, INC. | $140.97 | 2019-2025 | Bimzelx |
| Incyte Corporation | $124.37 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $119.21 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $110.74 | 2019-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $94.37 | 2020-2024 | Siliq |
| Kerecis Limited | $87.76 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Graftguide |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $71.95 | 2019-2023 | |
| Dermira, INC. | $56.40 | 2019-2021 | |
| Arcutis Biotherapeutics, INC. | $37.64 | 2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $35.00 | 2020-2021 | |
| Prugen, INC. Pharmaceuticals | $34.60 | 2019 | |
| Almirall LLC | $30.76 | 2019-2023 | Klisyri |
| Medtronic, INC. | $30.01 | 2022 | |
| Epi Health, LLC | $27.17 | 2022 | |
| Organogenesis INC. | $25.18 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.08 | 2025 | Spevigo |
| Celgene Corporation | $22.03 | 2024 | Sotyktu |
| Biofrontera INC. | $21.78 | 2022 | |
| Dermavant Sciences, INC. | $21.21 | 2023 | Vtama |
| Paratek Pharmaceuticals, INC. | $19.97 | 2022 | |
| Journey Medical Corporation | $18.45 | 2022 | |
| Mylan Pharmaceuticals INC. | $16.57 | 2019 | |
| Organon LLC | $15.89 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $15.44 | 2025 | Ycanth |
| Aclaris Therapeutics, INC. | $15.09 | 2019 | |
| Amgen INC. | $13.06 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shayna Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.